You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Nucala logo

Product menu

NA
WEBINARS & RESOURCES

RWE OF NUCALA USE IN SEVERE EOSINOPHILIC ASTHMA PATIENTS WITH CO-MORBID NASAL POLYPS

Prof. Patrick Mitchell

00:00
00:00

DURABLE DISEASE
CONTROL IN SEA:

DEMONSTRATED THROUGH REAL-WORLD EVIDENCE1,2

00:00
00:00

Need help with this product?

Request contact

Connect with a representative

References

  1. Nucala Summary of Product Characteristics. Available at https://www.medicines.ie/medicines/nucala-100-mg-powder-for-solution-for-injection-33145/spc#tabs. Last accessed March 2025.
  2. Caruso C. Canoica GW, Patel M. Smith A. Liu MC, Alfonso-Cristancho R et of. international, prospective study of mepoilzumab in severe asthma: REALITI-A at 2 yrs. Abstract presented at ERS Congress, 4-6 September 2022; Barcelona, Spain.

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

© 2025 - 2026 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.

PM-IE-MPL-WCNT-250001 | January 2025

Welcome to GSK’s product website

Here you will find information about GSK’s medicines and vaccines

I'm a healthcare professional registered in Ireland 

Important notice: this site is intended for healthcare professionals registered in Ireland. By entering this site, you are confirming that you are a healthcare professional registered in Ireland. This site may contain promotional information.

I'm a member of the public in Ireland

Since you are not a healthcare professional, you will be re-directed to our public site.

PM-IE-NA-WCNT-230003